Asia Myelodysplastic Syndrome (MDS) Registry

Starting soon

Conditions studied: Myelodysplastic Syndromes (MDS)

In brief

The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.

Key facts

Study ID

NCT07355478

Run by

Bristol-Myers Squibb

People needed

500

Starts

2026-03-26

Expected to finish

2027-09-30

Last updated by the study team

2026-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:
• Aged at least 18 years at initial diagnosis of MDS
• Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
• Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate
• Inclusion criteria for the prospective enrolment of MDS participants:
• Aged at least 18 years at initial diagnosis of MDS; and
• Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and
• Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate

You may not qualify if…

• None

Where it is running

• Local Institution - 0003 — Singapore, Singapore
• Local Institution - 002 — Seoul, Seoul Teugbyeolsi, South Korea
• Local Institution - 0001 — Taipei, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.